Chief Medical Officer
Martina Flammer, M.D., MBA is the Chief Medical Officer at Insmed Incorporated (INSM), a role she has held since December 2019.[[1]](https://fintool.com/app/research/companies/INSM/people/martina-flammer)[[4]](https://insmed.com/company/management-team/)[[6]](https://www.sec.gov/Archives/edgar/data/1104506/000110450625000018/insm-20250403.htm) Aged 61 and based in New York, NY, she oversees global clinical development, regulatory affairs, drug safety, and medical affairs, contributing to key achievements such as 19% year-over-year ARIKAYCE revenue growth in 2024, positive ASPEN data, brensocatib NDA acceptance with Priority Review, and IND clearance for INS1201.[[1]](https://fintool.com/app/research/companies/INSM/people/martina-flammer) Recently, as a corporate insider, she sold 1,887 shares of INSM stock at $186.19 per share on January 9, 2026.[[5]](https://www.ainvest.com/news/insmed-ceo-lewis-william-buys-sells-shares-january-2026-2601/)
Dr. Flammer earned her M.D. from the University of Vienna Medical School and an MBA from NYU Stern School of Business.[[1]](https://fintool.com/app/research/companies/INSM/people/martina-flammer)[[2]](https://patientworthy.com/2023/09/13/understanding-mac-lung-disease-pah-bronchiectasis-dr-flammer/)[[3]](https://rocketreach.co/martina-flammer-email_32354045) Her career spans over two decades in biopharma, beginning with training in internal and emergency medicine, followed by roles at Pfizer (2000–2011) in R&D across drug development and access, and progressive leadership positions at Boehringer Ingelheim from 2012–2019, including Senior Global Medical Director in Virology, VP of Medicine, Regulatory Affairs & Pharmacovigilance, VP Clinical Development & Medical Affairs, and Head of Corporate Division Customer Value.[[1]](https://fintool.com/app/research/companies/INSM/people/martina-flammer)[[2]](https://patientworthy.com/2023/09/13/understanding-mac-lung-disease-pah-bronchiectasis-dr-flammer/) At Insmed, she emphasizes patient-centricity in rare diseases like MAC lung disease and bronchiectasis.[[2]](https://patientworthy.com/2023/09/13/understanding-mac-lung-disease-pah-bronchiectasis-dr-flammer/)
View full insider profile →
Discussion